Back to today’s briefing

Story perspectives

FDA Streamlines Drug Approvals; Pfizer Acquires Metsera for $4.9B

9/25/2025

23 3

Summary

Story summary

FDA releases a draft plan to guide rare-disease drugmakers in expediting approvals.
Phase III trial of bemdaneprocel for Parkinson’s disease has begun, aiming to extend ON-time.
In January 2026, the European Commission will implement new Variations Guidelines to streamline post-approval changes.
Pfizer plans to acquire Metsera for $4.9 billion, adding obesity and cardiometabolic clinical-stage programs.

1 of 1

Story summary

FDA releases a draft plan to guide rare-disease drugmakers in expediting approvals.
Phase III trial of bemdaneprocel for Parkinson’s disease has begun, aiming to extend ON-time.
In January 2026, the European Commission will implement new Variations Guidelines to streamline post-approval changes.
Pfizer plans to acquire Metsera for $4.9 billion, adding obesity and cardiometabolic clinical-stage programs.